Lung lesions in post-COVID syndrome: Conclusion of the Council of Experts dated April 26, 2022
https://doi.org/10.18093/0869-0189-2022-32-5-774-781
About the Authors
G. L. IgnatovaRussian Federation
Galina L. Ignatova, Doctor of Medicine, Professor, Head of Department of Therapy, Institute of Postgraduate Physician Training
ul. Vorovskogo 64, Chelyabinsk, 454092
A. Yu. Petukhova
Russian Federation
Anna Yu. Petukhova, Candidate of Medicine, pulmonologist, allergist-immunologist, Head of the Department of Allergology and Immunology
ul. Serafimy Deryabinoy 34, Ekaterinburg, 620102
L. N. Novikova
Russian Federation
Lyubov N. Novikova, Candidate of Medicine, Associate Professor, Department of Pulmonology, Faculty of Postgraduate Physician Training
ul. L`va Tolstogo 6–8, Saint-Petersburg, 197022
V. P. Sereda
Russian Federation
Vitaly P. Sereda, Doctor of Medicine, Associate Professor, Senior Lecturer, Department of Propaedeutics of Internal Diseases, Federal State Budgetary Military Educational Institution of Higher Education “Military Medical Academy named after S.M.Kirov” of the Ministry of Defence of the Russian Federation, Deputy chief physician for inpatient care, pulmonologist, Limited Liability Company “My Medical Center”
ul. Akademika Lebedeva, Saint-Petersburg, 6194044,
Cheboksarskiy per. 1/6 lit. “A”, Saint-Petersburg, 191186
N. V. Teplova
Russian Federation
Natalia V. Teplova, Doctor of Medicine, Professor, Head of the Department of Clinical Pharmacology Medical Faculty
ul. Ostrovityanova 1, Moscow, 117997
O. A. Mubarakshina
Russian Federation
Olga A. Mubarakshina, Candidate of Medicine, Associate Professor, Department of Clinical Pharmacology
ul. Studencheskaya 10, Voronezh, 394622
References
1. Donnelly J.P., Wang X.Q., Iwashyna T.J. et al. Readmission and death after initial hospital discharge among patients with COVID-19 in a large multihospital system. JAMA. 2021; 325 (3): 304–306. DOI: 10.1001/jama.2020.21465.
2. Ambardar S.R. Hightower S.L., Huprikar N.A. et al. Post-COVID-19 pulmonary fibrosis: novel sequelae of the current pandemic. J. Clin. Med. 20221; 10 (11): 2452. DOI: 10.3390/jcm10112452.
3. Antoniou K.M., Vasarmidi E., Russell A.-M. et al. European Respiratory Society statement on long COVID-19 follow-up. Eur. Respir. J. 2022; in press. DOI: 10.1183/13993003.02174-2021.
4. Funke-Chamboura M., Bridevaux P.-O., Clarenbache C.F. et al. Swiss recommendations for the follow-up and treatment of pulmonary long COVID. Respiration. 2021; 100 (8): 826–841. DOI: 10.1159/000517255.
5. Kaber G., Kratochvil M.J., Burgener E.B. et al. Hyaluronan is abundant in COVID-19 respiratory secretions. medRxiv Preprint. 2020; Sept. 11. DOI: 10.1101/2020.09.11.20191692.
6. Osmanov I.M., Spiridonova E., Bobkova P. et al. Risk factors for long COVID in previously hospitalised children using the ISARIC global follow-up protocol: a prospective cohort study. Eur. Respir. J. 2021; July 1: 2101341. DOI: 10.1183/13993003.01341-2021. Epub ahead of print. PMID: 34210789.
Review
For citations:
Ignatova G.L., Petukhova A.Yu., Novikova L.N., Sereda V.P., Teplova N.V., Mubarakshina O.A. Lung lesions in post-COVID syndrome: Conclusion of the Council of Experts dated April 26, 2022. PULMONOLOGIYA. 2022;32(5):774-781. (In Russ.) https://doi.org/10.18093/0869-0189-2022-32-5-774-781